LOL, DayDreeming,
Someone should elaborate on how a Reverse Merger works for those who don't understand.
The accredited investors and company principal in Oncolix, will be issued shares as the private company becomes public.
The bulk of those shares are restricted for at least one year. In the case of GHC, they have a 15 month lock up along with company.
Those shares wont hit the float for a long time.
There will be some shares issued in lieu of cash, on interest on a quarterly basis on convertible notes that aren't due until late 2018.
Nobody will be able to just dump a 100,000,000 into the float.
This is just the reality of a reverse merger that has accredited investment already onboard.
Let not forget that accredited investment in Oncolix includes Ernest Mario.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
I think we are looking good once we get the FINRA system change out of the way.
GLTU, IMO and FWIW.
